▶ TB-500 · SUBTOPIC · DOSING LITERATURE
TB-500 Dosing Literature
For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.
SCOPE OF THIS PAGE
This page documents the published-literature dose ranges that appear in trials and animal studies of TB-500. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.
ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH
The published research record for TB-500 reports the following route(s) of administration: Subcutaneous, Intramuscular. Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of TB-500.
PHARMACOKINETIC HALF-LIFE
Published pharmacokinetic data report a half-life for TB-500 of approximately ~2 hours (rat). Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.
CITED DOSE RANGES IN THE LITERATURE
The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of TB-500. Refer to the original publication for full protocol detail.
- Sosne G, Qiu P, Goldstein AL, Wheater M (2010) reports the TB-500 protocol used in Biological activities of thymosin beta4 defined by active sites in short peptide sequences, published in FASEB J. PMID 20179146. See the source for the protocol-level dose range, frequency, and duration. link
- Bock-Marquette I, Saxena A, White MD, et al. (2004) reports the TB-500 protocol used in Thymosin beta-4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair, published in Nature. PMID 15565145. See the source for the protocol-level dose range, frequency, and duration. link
- Goldstein AL, Hannappel E, Kleinman HK (2005) reports the TB-500 protocol used in Thymosin beta-4: actin-sequestering protein moonlights to repair injured tissues, published in Trends Mol Med. PMID 16099219. See the source for the protocol-level dose range, frequency, and duration. link
DOSING Q+A FROM LITERATURE
The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.
▶ What is the half-life of TB-500?
Animal pharmacokinetic data report a plasma half-life around 2 hours, with longer tissue residence in cardiac and dermal sites.
▶ How is TB-500 reconstituted?
Reconstitute lyophilized TB-500 with USP-grade sterile diluent per laboratory protocol. The PEPPUDEX /calculator returns the volume-per-dose math.
▶ How long do TB-500 cycles last in animal studies?
Animal protocols vary from single-dose cardiac-MI experiments to 4–6 week dermal wound-healing studies. Community-reported research cycles cite 4–6 week loading phases at 2–5 mg/week followed by maintenance, though these are not clinical recommendations.
STORAGE OF THE REFERENCE COMPOUND
Lyophilized · 4 °C 24 months, −20 °C indefinite
Reconstituted · 2–8 °C, 28 days
Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.
RECONSTITUTION MATH (CALCULATOR)
The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.
REGULATORY CONTEXT
FDA · Not FDA-approved for any human use. Research-use only.
WADA · Prohibited at all times under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) · Thymosin Beta-4 and its derivatives named explicitly in the 2018 Prohibited List update.
RELATED PAGES
▶ LAST UPDATED · 2026-05-19